


PHARMACEUTICAL 2022



Zomedica Corp. Rank 38 of 475







PHARMACEUTICAL 2022



Zomedica Corp. Rank 38 of 475



The relative strengths and weaknesses of Zomedica Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zomedica Corp. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Zomedica Corp. is the variable Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 151%, being 428% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	200,408
Cost of Goods Sold	1,079
Intangible Assets	76,807
Liabilities, Current	4,340
Liabilities, Non-Current	1,465
Other Assets	1,979
Other Compr. Net Income	-1.7
Other Expenses	-2,321
Other Liabilities	3,709
Other Net Income	-403
Property and Equipment	1,206
Research and Development	1,673
Revenues	4,133
Selling, General and Administrative Expense	22,749

Output Variable	Value in 1000 USD
Assets	280,399
Liabilities	9,514
Expenses	23,180
Stockholders Equity	270,885
Net Income	-19,450
Comprehensive Net Income	-19,451
Economic Capital Ratio	151%